Pharmaceutical Information |
Drug Name |
Bedaquiline |
Drug ID |
BADD_D00221 |
Description |
Bedaquiline is a bactericidal antimycobacterial drug. Chemically it is a diarylquinoline. FDA approved on December 28, 2012. |
Indications and Usage |
Bedaquiline is indicated as part of combination therapy in adults (≥ 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB). |
Marketing Status |
approved |
ATC Code |
J04AK05 |
DrugBank ID |
DB08903
|
KEGG ID |
D09872
|
MeSH ID |
C493870
|
PubChem ID |
5388906
|
TTD Drug ID |
D0Y4QG
|
NDC Product Code |
Not Available |
UNII |
78846I289Y
|
Synonyms |
bedaquiline | (1R,2S)-1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-(3-fluorophenyl)-1-phenyl-butan-2-ol | R207910 | TMC207 | AIDS222088 | AIDS-222089 | bedaquiline fumarate |
|
Chemical Information |
Molecular Formula |
C32H31BrN2O2 |
CAS Registry Number |
843663-66-1 |
SMILES |
CN(C)CCC(C1=CC=CC2=CC=CC=C21)(C(C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O |
Chemical Structure |
|
|
ADRs Induced by Drug |
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|